Sort
10,766 grants matching “checkpoint inhibitor”
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
$396,958Weidong Xu · Endeavor Health Clinical Operations · R01 · FY2024 · CA
Double-Strand Break Sensing, Signaling, and Repair
$396,932John A Tainer · University Of Calif-Lawrenc Berkeley Lab · P01 · FY2014 · CA
Induction of interferon response by chromatin damaging anti-cancer therapy
$396,881Katerina V Gurova · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA
Induction of interferon response by chromatin damaging anti-cancer therapy
$396,881Katerina V Gurova · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Overcoming Resistance Mechanisms to Anaplastic Lymphoma Kinase Inhibitors
$396,625Aaron N Hata · Massachusetts General Hospital · R01 · FY2024 · CA
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
$396,457Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R01 · FY2014 · CA
REGULATION AND ADAPTIVE MECHANISMS OF ONCOGENIC RAS/ERK SIGNALING
$396,453Poulikos I Poulikakos · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities
$396,432Brent Allen Hanks · Duke University · R01 · FY2021 · CA
Covalent Protein Binders for Cancer Research and Therapy
$396,134Lei Wang · University Of California, San Francisco · R01 · FY2023 · CA
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
$396,116Binfeng Lu · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Development of IDO PET agents for immunotherapy
$396,007Zibo Li · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA
Development of IDO PET agents for immunotherapy
$396,007Zibo Li · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
Mechanisms of Intestinal Tumorigenesis
$395,882Vincent W. Yang · Emory University · R01 · FY2010 · CA
Targeting tumorigenic pathways in glioblastoma with oncolytic HSV
$395,770Samuel D Rabkin · Massachusetts General Hospital · R01 · FY2021 · CA
Targeting tumorigenic pathways in glioblastoma with oncolytic HSV
$395,770Samuel D Rabkin · Massachusetts General Hospital · R01 · FY2019 · CA
Targeting tumorigenic pathways in glioblastoma with oncolytic HSV
$395,770Samuel D Rabkin · Massachusetts General Hospital · R01 · FY2020 · CA
Development of Therapeutic Cancer Vaccine
$395,738Haifa Shen · Immunoq Therapeutics Inc. · R41 · FY2022 · CA
HCMV regulation of monocyte/macrophage host cell signaling in viral reactivation
$395,700Andrew D Yurochko · Oregon Health & Science University · P01 · FY2022 · AI
Development of a tumor-retentive immunostimulant as adjunct therapy for solid tumor cancers
$395,595Marcus Laird Forrest · Kinimmune, Inc. · R41 · FY2022 · CA
Targeting vulnerabilities of PPM1D-mutant gliomas
$395,535Pratiti Bandopadhayay · Dana-Farber Cancer Inst · R37 · FY2023 · CA
Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
$395,516Minah Kim · Columbia University Health Sciences · R37 · FY2024 · CA
Role of melanoma-PD-1 in cancer progression
$395,502Tobias Schatton · Brigham And Women'S Hospital · R01 · FY2017 · CA
Role of melanoma-PD-1 in cancer progression
$395,502Tobias Schatton · Brigham And Women'S Hospital · R01 · FY2021 · CA
Role of melanoma-PD-1 in cancer progression
$395,502Tobias Schatton · Brigham And Women'S Hospital · R01 · FY2020 · CA
Role of melanoma-PD-1 in cancer progression
$395,501Tobias Schatton · Brigham And Women'S Hospital · R01 · FY2018 · CA